Roxadustat Trials

Our most advanced product candidate, roxadustat, is progressing through a global Phase 3 clinical development program for the treatment of anemia in chronic kidney disease, and recently entered Phase 3 development in the U.S. and will soon start Phase 2/3 development in China for treatment of anemia associated with myelodysplastic syndromes. The goal of these clinical studies is to evaluate the safety and efficacy of the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor therapy for the treatment of anemia.